Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Cancer Science

Volumn 99, Issue 1, 2008, Pages 179-184

  Oki, Yasuhiro ^a   Ogura, Michinori ^a   Kato, Harumi ^a   Kikuchi, Ako ^a   Taji, Hirofumi ^a   Kagami, Yoshitoyo ^a   Oshiro, Aya ^a   Tsujimura, Akane ^a   Yamamoto, Kazuhito ^a   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MIDDLE AGED; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

EID: 36949022946     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00662.x     Document Type: Article

References (15)

1. Ogura M, Kagami Y, Taji H et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 2003; 77: 503-11.
2. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-22.
3. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP -an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12: 1169-76.
4. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
5. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
6. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-8.
7. Hicks L, Buckstein R, Mangel J et al. Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma (Abstract). Blood 2006; 108: 3067.
8. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
9. Mey UJ, Olivieri A, Orlopp KS et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: A matched-pair analysis. Leuk Lymphoma 2006; 47: 2558-66.
10. Hagberg H, Gisselbrecht C: CORAL Study Group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 2006; 17 (Suppl 4): Iv31-2.
11. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-8.
12. Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921-3.
13. Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann Oncol 2007; 18: 364-9.
14. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691-4.
15. Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B. Cancer 1981; 48: 1927-30.